KENILWORTH, N.J., Aug. 19 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) announced today that ASMANEX(R) TWISTHALER(R) 110 mcg (mometasone furoate ...

Mometasone furoate 110mcg/inh, 220mcg/inh; pwd for oral inhalation; with dose counter. Maintain regular regimen. Prescribe a short-acting, inhaled β2-agonist for acute symptoms. Re-evaluate ...

Mar. 23 -- TUESDAY, Feb. 5 (HealthDay News) -- Schering-Plough's Asmanex Twisthaler, an inhaled steroid designed to prevent asthma attacks, has been approved by the U.S. Food and Drug Administration ...

asthma inhaler overweight The FDA has approved updated labeling for Asmanex HFA (mometasone furoate; Merck) and Dulera (mometasone furoate, formoterol fumarate; Merck) to include use in pediatric ...

NEW YORK (MarketWatch) -- Schering-Plough Corp. lifted 27 cents, or 1.5 percent, to $27.29 in premarket trade Thursday after the U.S. Food & Drug Administration approved the Asmanex Twisthaler 220 mcg ...

A new inhaled steroid treatment for preventing asthma attacks in young children has been approved by the Food and Drug Administration, the drugmaker Schering-Plough Corp. said. Its Asmanex Twisthaler ...

KENILWORTH, N.J. The Food and Drug Administration has approved Schering-Plough’s asthma inhaler Asmanex twisthaler 110 mcg for the maintenance of asthma as a preventive therapy in patients 4 to 11 ...

April 14, 2005 -- The U.S. Food and Drug Administration (FDA) has approved mometasone furoate inhalation powder for the maintenance treatment of asthma as prophylactic therapy in patients aged 12 ...

In a joint statement today, Schering-Plough and Novartis announced changes to the collaboration agreements regarding both companies’ respiratory portfolios. Schering Plough will assume exclusive ...

If you have not heard already, one of the most popular inhalers has been discontinued by its manufacturer since January 1. GlaxoSmithKline (GSK) has stopped producing Flovent, which comes as a metered ...